Leerink Partnrs Has Positive Outlook of Biohaven Q3 Earnings

Biohaven Ltd. (NYSE:BHVN) – Analysts at Leerink Partnrs raised their Q3 2025 earnings per share (EPS) estimates for shares of Biohaven in a note issued to investors on Wednesday, November 5th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings of ($1.74) per share for the quarter, up from their prior estimate of ($1.76). The consensus estimate for Biohaven’s current full-year earnings is ($8.90) per share. Leerink Partnrs also issued estimates for Biohaven’s Q4 2025 earnings at ($1.77) EPS, FY2025 earnings at ($7.62) EPS, FY2026 earnings at ($3.60) EPS, FY2027 earnings at ($3.00) EPS and FY2028 earnings at ($2.35) EPS.

Several other equities analysts have also recently weighed in on the company. Bank of America cut Biohaven from a “buy” rating to a “neutral” rating and set a $10.00 price target on the stock. in a report on Wednesday, November 5th. Citigroup began coverage on Biohaven in a report on Wednesday, September 17th. They issued a “buy” rating and a $28.00 target price on the stock. Raymond James Financial reissued a “strong-buy” rating on shares of Biohaven in a research report on Wednesday, November 5th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target (down previously from $54.00) on shares of Biohaven in a research report on Tuesday, August 12th. Finally, TD Cowen lowered their price objective on shares of Biohaven from $50.00 to $15.00 and set a “buy” rating on the stock in a research note on Wednesday, November 5th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $34.21.

Biohaven Trading Up 8.9%

Shares of BHVN stock opened at $8.48 on Monday. The company has a current ratio of 3.82, a quick ratio of 3.82 and a debt-to-equity ratio of 1.91. Biohaven has a 12-month low of $7.48 and a 12-month high of $52.76. The stock has a market capitalization of $897.10 million, a P/E ratio of -1.12 and a beta of 1.10. The firm’s 50 day moving average is $14.84 and its 200 day moving average is $15.42.

Biohaven (NYSE:BHVN) last announced its quarterly earnings results on Monday, November 10th. The company reported ($1.64) EPS for the quarter, topping analysts’ consensus estimates of ($1.91) by $0.27.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of BHVN. PNC Financial Services Group Inc. increased its stake in Biohaven by 53.7% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,783 shares of the company’s stock worth $43,000 after buying an additional 623 shares in the last quarter. Emerald Mutual Fund Advisers Trust boosted its stake in shares of Biohaven by 0.4% in the third quarter. Emerald Mutual Fund Advisers Trust now owns 173,656 shares of the company’s stock worth $2,607,000 after acquiring an additional 657 shares during the period. RWA Wealth Partners LLC grew its position in shares of Biohaven by 7.0% during the first quarter. RWA Wealth Partners LLC now owns 12,622 shares of the company’s stock worth $303,000 after purchasing an additional 822 shares in the last quarter. SVB Wealth LLC bought a new stake in Biohaven during the 1st quarter valued at approximately $25,000. Finally, Elkhorn Partners Limited Partnership lifted its holdings in Biohaven by 26.1% in the 2nd quarter. Elkhorn Partners Limited Partnership now owns 5,800 shares of the company’s stock worth $82,000 after purchasing an additional 1,200 shares in the last quarter. Hedge funds and other institutional investors own 88.78% of the company’s stock.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.